Targeted HDAC 8 Inhibitors for Managing Kidney Disease

University of Pittsburgh researchers have developed novel HDAC 8 inhibitors based on indole amino ketones, which show promise for the treatment of kidney disease. These inhibitors are designed to target and modulate histone deacetylase (HDAC) activity, offering a potential therapeutic approach for managing kidney disease.

Description

The invention involves the design and synthesis of new HDAC 8 inhibitors using indole amino ketones. These compounds have been developed to specifically inhibit HDAC 8, an enzyme implicated in various pathological conditions, including kidney disease. The inhibitors are synthesized through a hybridization approach, combining elements from previously known compounds to enhance their efficacy and specificity. The technology is currently at the prototype stage, with initial data demonstrating its potential utility in treating kidney disease.

Applications

• Treatment of kidney disease
• Therapeutic research and development
• Biomedical research on HDAC inhibitors

Advantages

This technology offers a novel approach to treating kidney disease by specifically targeting HDAC 8. The indole amino ketone-based inhibitors are designed to be highly effective and specific, potentially reducing side effects associated with non-specific HDAC inhibition. The development of these inhibitors could lead to new therapeutic options for patients with kidney disease, improving their quality of life and clinical outcomes.

Invention Readiness

The technology is currently at the prototype stage, with HDAC 8 inhibitors validated to be highly selective and less toxic (compared to the FDA approved HDAC inhibitors). Initial studies have shown promising results using organoid models and preclinical data is available. Further development is focused on refining the compounds and evaluating their efficacy of kidney disease through trials.

IP Status

https://patents.google.com/patent/WO2025171382A1